APP Pharmaceuticals, LLC, a Fresenius Kabi Company, has acquired benztropine mesylate injection, levetiracetam injection and tranexamic acid injection from Nexus Pharmaceuticals, Inc. Under terms of the agreement APP takes complete ownership of these products and becomes the Abbreviated New Drug Application (ANDA) holder.
"The addition of these products broadens an already extensive portfolio of injectable APP critical care products," said John Ducker, president and chief executive officer of APP Pharmaceuticals. "As leaders in the reliable supply of sterile generic injectable drugs, APP will continue to identify, develop and market products to meet customer needs."
Benztropine mesylate injection, USP (1mg/mL, 2 mL) is therapeutically equivalent to the reference-listed drug Cogentin. Levetiracetam injection (100 mg/ml, 5 mL) is therapeutically equivalent to the reference-listed drug Keppra. Tranexamic acid injection (100 mg/mL, 10 mL) is therapeutically equivalent to the reference-listed drug Cyklokapron. According to IMS Health, in 2011 these three products combined represented a total market value of more than $90 million in the United States.
APP Pharmaceuticals is a fully-integrated pharmaceutical company that develops, manufactures and markets injectable pharmaceutical products with a primary focus on the oncology, anti-infective, anesthetic/analgesic and critical care markets.
Fresenius Kabi AG is the leader in infusion therapy and clinical nutrition in Europe and in its most important countries of Latin America and Asia Pacific.